Comparison glycemic excursions of short-acting glucagon-like peptide 1(GLP-1) Receptor Agonists(RAs)(Liraglutide) with long-acting GLP-1 RAs(Dulaglutide).

Trial Profile

Comparison glycemic excursions of short-acting glucagon-like peptide 1(GLP-1) Receptor Agonists(RAs)(Liraglutide) with long-acting GLP-1 RAs(Dulaglutide).

Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Apr 2018

At a glance

  • Drugs Dulaglutide (Primary) ; Liraglutide (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Apr 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top